Health Care/Hospital

Bridge Biotherapeutics Announces Positive Recommendation from the Independent Data Monitoring Committee of the BBT-877 Phase 2a Study in Idiopathic Pulmonary Fibrosis

* The independent data monitoring committee (IDMC) recommended the continuation of the BBT-877 Phase 2a trial based on the initial clinical data from the first 20 participants dosed with theinvestigational product * No safety concerns were raised based on the evaluation of the data presented ...

2023-10-26 07:00 1164

Positive results from first-in-human completely leadless CRT in the US, published in The Journal of the American College of Cardiology

SUNNYVALE, Calif., Oct. 25, 2023 /PRNewswire/ -- EBR Systems, Inc. (ASX:EBR), the medical device company developing wireless cardiac pacing systems, is proud to announce that positive results from the first completely leadless cardiac resynchronization therapy (CRT) ...

2023-10-26 00:00 1359

Neuragenex Brings Innovative Fibromyalgia Treatment to Patients Across the US

GULBERT, Ariz., Oct. 25, 2023 /PRNewswire/ -- Neuragenex, the national healthcare provider focused on non-pharmaceutical pain treatment, announced its continued expansion to bring relief to fibromyalgia patients across the country. With clinics now operating in Georgia, Texas, Illinois, Tenness...

2023-10-25 23:23 1204

Qilu Pharmaceutical announces the latest results from its clinical study on QL1706, in combination with chemotherapy, as a first-line treatment for recurrent or metastatic cervical cancer

JINAN, China, Oct. 25, 2023 /PRNewswire/ -- On October 22, Qilu Pharmaceutical unveiled the latest findings from a multicenter, single-arm Phase II clinical trial at the European Society for Medical Oncology (ESMO) Annual Congress 2023. This trial studied the use of QL1706 (iparomlimab and tuvonr...

2023-10-25 22:33 1787

Qilu Pharmaceutical announces the latest results from its clinical study on QL1706, in combination with chemotherapy, as a first-line treatment for recurrent or metastatic cervical cancer

JINAN, China, Oct. 25, 2023 /PRNewswire/ -- On October 22, Qilu Pharmaceutical unveiled the latest findings from a multicenter, single-arm Phase II clinical trial at the European Society for Medical Oncology (ESMO) Annual Congress 2023. This trial studied the use of QL1706 (iparomlimab and tuvonr...

2023-10-25 22:15 1676

First Patient Dosed for MRCT Phase 3 Study on First-Line LS-SCLC of Henlius Anti-PD-1 mAb Serplulimab in Europe

SHANGHAI, Oct. 25, 2023 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the first patient inEurope has been dosed in the international multi-centre phase 3 clinical trial (NCT05353257) of the company's self-developed anti-PD-1 mAb HANSIZHUANG (serplulimab) in combination ...

2023-10-25 21:15 1659

FDA Meeting Feedback Puts Turn Biotechnologies on Track to be First Longevity Company Taking Cell Rejuvenation Therapy to Clinic

* FDA INTERACT meeting reviews Turn Bio's ERA™ and eTurna™ technologies, approach and plans, paving way toward its IND * Company continues to pace industry's cell regeneration therapy progress MOUNTAIN VIEW, Calif., Oct. 25, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation compa...

2023-10-25 20:30 1457

NEWLY-LAUNCHED AMAZFIT ACTIVE AND AMAZFIT ACTIVE EDGE INTRODUCE A STYLISH WAY TO STAY ACTIVE & STAY HEALTHY

Tailored for the modern-day city consumer, the Amazfit Active and Amazfit Active Edge seamlessly blend style, functionality, and health, redefining what it means to live an active lifestyle. MILPITAS, Calif., Oct. 25, 2023 /PRNewswire/ -- Amazfit , a leading global smar...

2023-10-25 20:00 1606

ESAOTE's new S-scan Open redefines excellence in magnetic resonance imaging

GENOA, Italy, Oct. 25, 2023 /PRNewswire/ -- Esaote, a leading Italian company in ultrasound, dedicated MRI and healthcare IT,presents S-scan Open, the new configuration of S-scan,one of its best-selling MRI systems.  

2023-10-25 20:00 1835

Metabolon and Genomics England Announce Partnership to Characterize Hundreds of Rare Diseases and Advance Rare Disease Diagnosis

Alliance aims to enable the discovery of novel rare disease biomarkers to support faster diagnosis and more effective treatments MORRISVILLE, N.C., and LONDON, Oct. 25, 2023 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life sc...

2023-10-25 19:57 1145

Good Safety Profile and Antitumor Activity: Oral Presentation of Mabwell's 9MW2821 at 2023 ESMO

Shanghai, Oct. 25, 2023 /PRNewswire/ -- ESMO Congress 2023 was held in Madrid, Spain from October 20-24, the preliminary results of the Phase I/II study of 9MW2821 (Nectin-4 targeting ADC) in patients with advanced solid tumors were reported by Dr.Jian Zhang of Fudan University Shanghai Cancer Ce...

2023-10-25 17:46 1375

FUTURE INVESTMENT INITIATIVE INSTITUTE RESOLVES TO REMOVE 5.4 TRILLION INVESTMENT GAP IN EMERGING MARKETS

RIYADH, Saudi Arabia, Oct. 25, 2023 /PRNewswire/ -- At the Future Investment Initiative (FII) inRiyadh today, a global summit, leaders and investors have today resolved to tackle ESG shortcomings in the form of a Resolution to Increase ESG Investment in Emerging Markets

2023-10-25 15:46 1645

AMS BioteQ Makes Debut at Medical Japan 2023: Bringing Innovative Healthcare into New Horizons

TAIPEI, Oct. 25, 2023 /PRNewswire/ -- Medical Japan Tokyo was held grandly from October 11 to 13, gathering medical professionals, manufacturers, medical institutions, and research units from around the world. AMS BioteQ Co., Ltd. made its first appearance in the exhibition and became one of the ...

2023-10-25 13:06 1362

GC Cell Joins U.S Cancer Moonshot Project

Brining Expertise in NK Cell Therapy to Advance Efforts in Cancer Prevention, early detection, and treatment development ▶ New focus on NK cell therapy for conquering cancer ▶ GC Cell seizes the opportunity to share its cell gene therapy technology and capabilities globally ▶ Development of sol...

2023-10-25 11:27 1365

Snapdragon Chemistry, a Cambrex Company, Recognized with CPhI Pharma Award for API Development

EAST RUTHERFORD, N.J, Oct. 25, 2023 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced that Snapdragon Chemistry has been selected as the winner of the API Development Award, presented at the CPhI Pharma Awards inBarcelona, Spain....

2023-10-25 04:18 1597

Cyrus K. Mirsaidi Named Global CEO to Bridgewest Perth Pharma

--Industry veteran to lead growth for company's CDMO and pharmaceutical supply divisions, NovaCina and LumaCina-- MIAMI and PERTH, Australia, Oct. 25, 2023 /PRNewswire/ -- Bridgewest Perth Pharma, a global pharmaceutical supply and manufacturing company, announced today thatCyrus K. Mirsaidi is ...

2023-10-24 23:17 1274

TidetronBioworks Illuminated in Global Spotlight at WFF 2023 for Sustainable Power

ROME, Oct. 24, 2023 /PRNewswire/ -- The World Food Forum (WFF) 2023, a global platform dedicated to addressing the challenges ofSustainable Development Goals (SDGs) and better food future, convened its flagship event, featuring an influential private s...

2023-10-24 22:31 1244

Wolters Kluwer Applauded by Frost & Sullivan for Improving Healthcare Efficiencies, Quality, and Outcomes and for Its Competitive Strategies

Wolters Kluwer uniquely leverages its expertise to meet market and customer needs, positioning it to capitalize on new growth opportunities and lead in healthcare conversational AI. SAN ANTONIO, Oct. 24, 2023 /PRNewswire/ -- Frost & Sullivan recently researched the conversational artificial inte...

2023-10-24 21:30 1252

First Immunotherapy Success in TKI-Resistant Lung Cancer Setting Demonstrates Power of AI-driven Immune Phenotyping by Lunit SCOPE IO - newly published in JCO

* Lunit SCOPE IO pivotal in first phase III trial successfully showing the efficacy of immunotherapy + chemotherapy for NSCLC patients with EGFR or ALK mutation - published in theJournal of Clinical Oncology and accepted by ESMO for oral presentation SEOUL, South Korea, Oct. 24, 2023 /PRNewswir...

2023-10-24 21:00 1373

Phase Ib/II Results of Akeso's PD-1/CTLA-4 Bispecific Antibody for First-Line Treatment of Advanced Hepatocellular Carcinoma Published at 2023 ESMO

HONG KONG, Oct. 24, 2023 /PRNewswire/ -- Akeso announced poster presentation at the 2023 European Society for Medical Oncology (ESMO) Congress from its cadonilimab ( PD-1/CTLA-4 bispecific antibody) combined with lenvatinib for first-line treatment of Advanced Hepatocellular Carcinoma (HCC). The ...

2023-10-24 20:00 1066
1 ... 66676869707172 ... 802

Week's Top Stories